Standardization of the assessment process within telerehabilitation in chronic diseases: a scoping meta-review.
Chronic disease
Evaluation
Health technology assessment
Scoping meta-review
Telerehabilitation
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
02 Aug 2022
02 Aug 2022
Historique:
received:
28
05
2021
accepted:
07
07
2022
entrez:
2
8
2022
pubmed:
3
8
2022
medline:
5
8
2022
Statut:
epublish
Résumé
Telerehabilitation (TR) interventions are receiving increasing attention. They have been evaluated in various scientific areas through systematic reviews. However, there is a lack of data on how to standardize assessment and report on their domains to guide researchers across studies and bring together the best evidence to assess TR for chronic diseases. The aim of this study was to identify domains of assessment in TR and to qualitatively and quantitatively analyze how and when they are examined to gain an overview of assessment in chronic disease. A scoping meta-review was carried out on 9 databases and gray literature from 2009 to 2019. The keyword search strategy was based on "telerehabilitation", "evaluation", "chronic disease" and their synonyms. All articles were subjected to qualitative analysis using the Health Technology Assessment (HTA) Core Model prior to further analysis and narrative synthesis. Among the 7412 identified articles, 80 studies met the inclusion criteria and addressed at least one of the noncommunicable diseases (NCD) categories of cardiovascular disease (cardiovascular accidents), cancer, chronic respiratory disease, diabetes, and obesity. Regarding the domains of assessment, the most frequently occurring were "social aspect" (n = 63, 79%) (e.g., effects on behavioral changes) and "clinical efficacy" (n = 53, 66%), and the least frequently occurring was "safety aspects" (n = 2, 3%). We also identified the phases of TR in which the assessment was conducted and found that it most commonly occurred in the pilot study and randomized trial phases and least commonly occurred in the design, pretest, and post-implementation phases. Through the HTA model, this scoping meta-review highlighted 10 assessment domains which have not been studied with the same degree of interest in the recent literature. We showed that each of these assessment domains could appear at different phases of TR development and proposed a new cross-disciplinary and comprehensive method for assessing TR interventions. Future studies will benefit from approaches that leverage the best evidence regarding the assessment of TR, and it will be interesting to extend this assessment framework to other chronic diseases.
Sections du résumé
BACKGROUND
BACKGROUND
Telerehabilitation (TR) interventions are receiving increasing attention. They have been evaluated in various scientific areas through systematic reviews. However, there is a lack of data on how to standardize assessment and report on their domains to guide researchers across studies and bring together the best evidence to assess TR for chronic diseases.
AIMS AND OBJECTIVES
OBJECTIVE
The aim of this study was to identify domains of assessment in TR and to qualitatively and quantitatively analyze how and when they are examined to gain an overview of assessment in chronic disease.
METHODS
METHODS
A scoping meta-review was carried out on 9 databases and gray literature from 2009 to 2019. The keyword search strategy was based on "telerehabilitation", "evaluation", "chronic disease" and their synonyms. All articles were subjected to qualitative analysis using the Health Technology Assessment (HTA) Core Model prior to further analysis and narrative synthesis.
RESULTS
RESULTS
Among the 7412 identified articles, 80 studies met the inclusion criteria and addressed at least one of the noncommunicable diseases (NCD) categories of cardiovascular disease (cardiovascular accidents), cancer, chronic respiratory disease, diabetes, and obesity. Regarding the domains of assessment, the most frequently occurring were "social aspect" (n = 63, 79%) (e.g., effects on behavioral changes) and "clinical efficacy" (n = 53, 66%), and the least frequently occurring was "safety aspects" (n = 2, 3%). We also identified the phases of TR in which the assessment was conducted and found that it most commonly occurred in the pilot study and randomized trial phases and least commonly occurred in the design, pretest, and post-implementation phases.
CONCLUSIONS
CONCLUSIONS
Through the HTA model, this scoping meta-review highlighted 10 assessment domains which have not been studied with the same degree of interest in the recent literature. We showed that each of these assessment domains could appear at different phases of TR development and proposed a new cross-disciplinary and comprehensive method for assessing TR interventions. Future studies will benefit from approaches that leverage the best evidence regarding the assessment of TR, and it will be interesting to extend this assessment framework to other chronic diseases.
Identifiants
pubmed: 35918690
doi: 10.1186/s12913-022-08370-y
pii: 10.1186/s12913-022-08370-y
pmc: PMC9344755
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
984Informations de copyright
© 2022. The Author(s).
Références
Stud Health Technol Inform. 2009;145:231-48
pubmed: 19592797
Science. 1996 Nov 1;274(5288):740-3
pubmed: 8966556
J Am Heart Assoc. 2013 Nov 01;2(6):e000568
pubmed: 24185949
Endocrinol Diabetes Nutr (Engl Ed). 2019 May;66(5):330-337
pubmed: 30745121
J Telemed Telecare. 2011;17(6):281-7
pubmed: 21844172
JMIR Mhealth Uhealth. 2017 Dec 04;5(12):e187
pubmed: 29203459
Prev Med. 2019 Feb;119:132-144
pubmed: 30597226
Telemed J E Health. 2014 Jan;20(1):75-82
pubmed: 24205809
Telemed J E Health. 2021 Mar;27(3):239-246
pubmed: 32326849
Int J Med Inform. 2011 Jun;80(6):389-405
pubmed: 21481632
J Telemed Telecare. 2018 Jan;24(1):4-12
pubmed: 29320966
Prog Cardiovasc Dis. 2016 May-Jun;58(6):605-12
pubmed: 26902519
Cancer Treat Rev. 2019 Mar;74:1-14
pubmed: 30658289
J Med Internet Res. 2014 Sep 15;16(9):e210
pubmed: 25223398
PLoS One. 2017 Mar 1;12(3):e0173160
pubmed: 28249025
Am Psychol. 1989 Sep;44(9):1175-84
pubmed: 2782727
BMC Med Inform Decis Mak. 2018 Feb 20;18(1):12
pubmed: 29458358
PLoS One. 2017 Feb 2;12(2):e0170581
pubmed: 28152012
Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):281-9
pubmed: 19407659
Am Psychol. 2008 Apr;63(3):146-59
pubmed: 18377105
Worldviews Evid Based Nurs. 2014 Apr;11(2):81-8
pubmed: 24597522
Telemed J E Health. 2019 Jul;25(7):569-583
pubmed: 30124394
Telemed J E Health. 2013 Jan;19(1):48-53
pubmed: 22957502
Implement Sci. 2015 Apr 24;10:59
pubmed: 25906822
Diabetes Care. 2016 Nov;39(11):2089-2095
pubmed: 27926892
Diabetes Res Clin Pract. 2017 Sep;131:70-81
pubmed: 28692830
BMC Cancer. 2018 Mar 2;18(1):244
pubmed: 29499663
Adv Nutr. 2017 May 15;8(3):449-462
pubmed: 28507010
Stud Health Technol Inform. 1998;52 Pt 2:1330-4
pubmed: 10384677
BMC Health Serv Res. 2014 Jun 13;14:250
pubmed: 24923771
J Med Internet Res. 2018 Nov 23;20(11):e10971
pubmed: 30470678
JMIR Hum Factors. 2017 Oct 03;4(4):e24
pubmed: 28974481
J Med Internet Res. 2011 Sep 22;13(3):e65
pubmed: 21979293
JMIR Mhealth Uhealth. 2018 Jul 23;6(7):e10723
pubmed: 30037787
Implement Sci. 2016 Apr 14;11:52
pubmed: 27079375
PLoS One. 2015 Oct 14;10(10):e0139561
pubmed: 26465333
PLoS Med. 2009 Aug;6(8):e1000126
pubmed: 19688038
PLoS Med. 2009 Sep;6(9):e1000105
pubmed: 19753106
Eur J Prev Cardiol. 2015 Jan;22(1):35-74
pubmed: 23943649
Med Sci Sports Exerc. 1994 Nov;26(11):1400-4
pubmed: 7837962
PLoS One. 2018 Jan 5;13(1):e0189801
pubmed: 29304148
Eur Respir J. 2004 Jun;23(6):932-46
pubmed: 15219010
Diabet Med. 2011 Apr;28(4):455-63
pubmed: 21392066
J Med Internet Res. 2017 Jan 20;19(1):e26
pubmed: 28108429
J Med Internet Res. 2015 Feb 24;17(2):e52
pubmed: 25803266
Obes Rev. 2015 May;16(5):376-92
pubmed: 25753009
Sociol Health Illn. 2006 Jul;28(5):513-32
pubmed: 16910945
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Patient Educ Couns. 2019 Jun;102(6):1080-1089
pubmed: 30745178
Annu Rev Public Health. 2015 Mar 18;36:393-415
pubmed: 25785892
Obes Rev. 2014 Oct;15 Suppl 4:146-58
pubmed: 25196411
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Heart. 2016 Aug 1;102(15):1183-92
pubmed: 26936337
BMC Med Inform Decis Mak. 2016 Feb 25;16:26
pubmed: 26911326
Am J Med. 2014 Dec;127(12):1242.e1-10
pubmed: 25004456
J Med Internet Res. 2017 Aug 02;19(8):e281
pubmed: 28768610
Respirology. 2021 Jul;26(7):713-714
pubmed: 33904212
J Med Internet Res. 2018 Feb 02;20(2):e25
pubmed: 29396387
J Telemed Telecare. 2004;10(4):199-205
pubmed: 15273029
Eur J Prev Cardiol. 2015 Aug;22(8):959-71
pubmed: 25488550
Implement Sci. 2010 Sep 20;5:69
pubmed: 20854677
Curr Hypertens Rep. 2018 Aug 7;20(10):86
pubmed: 30088110
BMC Med Inform Decis Mak. 2013 Feb 11;13:23
pubmed: 23399513
Telemed J E Health. 2018 Nov;24(11):839-852
pubmed: 29470105
Int J Med Inform. 2006 Feb;75(2):125-37
pubmed: 16112893
Ann Allergy Asthma Immunol. 2018 Dec;121(6):680-691.e1
pubmed: 30352288
Diabetes Metab Syndr. 2019 Mar - Apr;13(2):1353-1357
pubmed: 31336491
Telemed J E Health. 2017 May;23(5):351-364
pubmed: 27792475
J Med Internet Res. 2015 Nov 16;17(11):e259
pubmed: 26573984
J Diabetes Complications. 2014 Mar-Apr;28(2):243-51
pubmed: 24332469
Ann Behav Med. 2014 Dec;48(3):323-36
pubmed: 24763972
J Med Internet Res. 2016 Sep 26;18(9):e256
pubmed: 27670360
J Med Internet Res. 2014 Apr 09;16(4):e104
pubmed: 24718852
BMJ. 2016 Mar 17;352:i1174
pubmed: 26988021
Respir Med. 2015 Jan;109(1):11-26
pubmed: 25464906
BMC Cardiovasc Disord. 2018 Feb 7;18(1):25
pubmed: 29415680
BMC Med Inform Decis Mak. 2016 Apr 22;16:46
pubmed: 27106263
Chron Respir Dis. 2009;6(2):91-7
pubmed: 19411570
Int J Telerehabil. 2010 Sep 24;2(1):15-22
pubmed: 25945169
Eur J Prev Cardiol. 2016 May;23(8):801-17
pubmed: 26490093
Stroke. 2009 Jul;40(7):2616-34
pubmed: 19423852
J Telemed Telecare. 2017 Feb;23(2):339-346
pubmed: 26843466
Psychooncology. 2017 Sep;26(9):1239-1253
pubmed: 28665554
Health Informatics J. 2009 Jun;15(2):122-46
pubmed: 19474225
J Cancer Surviv. 2019 Feb;13(1):97-107
pubmed: 30635865
JMIR Mhealth Uhealth. 2015 Mar 11;3(1):e27
pubmed: 25760773
Can J Diabetes. 2019 Feb;43(1):51-58.e3
pubmed: 30026048
Respir Med. 2019 Oct - Nov;158:78-88
pubmed: 31614305
Annu Rev Public Health. 2021 Apr 1;42:135-158
pubmed: 33467924
Medicine (Baltimore). 2018 Oct;97(43):e12962
pubmed: 30412116
J Med Internet Res. 2007 May 27;9(2):e15
pubmed: 17537718
JMIR Mhealth Uhealth. 2019 Oct 25;7(10):e12612
pubmed: 31654566
BMC Health Serv Res. 2018 Oct 4;18(1):757
pubmed: 30286761
Arch Phys Med Rehabil. 2019 Jan;100(1):115-127
pubmed: 30171827
J Cancer Surviv. 2015 Dec;9(4):660-82
pubmed: 25757733
Am J Prev Med. 2019 Jun;56(6):894-903
pubmed: 31003801
JMIR Mhealth Uhealth. 2017 May 02;5(5):e60
pubmed: 28465282
BMC Med. 2012 Nov 22;10:144
pubmed: 23171675
J Med Internet Res. 2010 Jun 28;12(2):e24
pubmed: 20584698
Respir Med. 2014 Apr;108(4):628-37
pubmed: 24451438
Disabil Rehabil. 2009;31(6):427-47
pubmed: 18720118
J Telemed Telecare. 2007;13(5):217-20
pubmed: 17697506
J Med Internet Res. 2016 Apr 19;18(4):e86
pubmed: 27095386
Clin Transl Sci. 2015 Feb;8(1):77-81
pubmed: 25041546
J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2583-2591
pubmed: 30954644
J Med Internet Res. 2017 Oct 12;19(10):e348
pubmed: 29025693
J Telemed Telecare. 2012 Dec;18(8):447-50
pubmed: 23209266